Drug Interaction- summary-

+ Iobenguane I 123

Antidepressants eg. amitriptyline, imipramine , SSRIs
Antihypertensives eg reserpine, labetalol
Cocaine
Sympathomimetic amines eg. ephedrine, phenylephrine, pseudoephedrine

drugs that interfere with norephinephrine may decrease the uptake of iobenguane  in
neuroendocrine tumors and lead to false -negative imaging results.  When feasible
stop these drugs before logenguane administration ( for atleast 5 biological half-lives)
and monitor patients for occurrence of clinically significant withdrawal symptoms,
especially patients with elevated levels of circulating catecholamine and their
metabolites   

Detection of pheochromocytoma/neuroblastoma

Adverse reactions are mild to moderate

dizziness, flushing, injection site reactions, hemorrhage, pruritus or rash

Knownhypersensitivity to the drug

Special Precautions/Warnings-

Concomittant thyroid accumulation - failure to block thyroid uptake of iodine 123 may
result in an increased long-term risk for thyroid neoplasia.
Administer thyroid blocking medications before iobenguane 1 123 administration

Hypertension- prior to iobenguane 1 123 administration ensure emergency cardiac
and antihypertensive treatments are readily available,

Hypersensitivity - have anaphylactic and hypersentivity treatment measures  available
prior to iobguane 1 123 administration

Renal function impairment - Iboguane I 123 safety and efficacy have not been established
in these patients

Pregnancy - give Iobuguane I 123 to a pregnant women only if clearly needed

Lactation- consider interrupting breast feeding for 6 days  after iobeguane I 123 
administration  in order to minimise risks to breast- feeding infants

Children- safety and effectivness in 1 month to 16 years of age have not been studied

Elderly - consider assesssment of renal function  in elderly patients prior to
iobenguane administration

Indication-

Detection of pheochromocytoma/neuroblastoma

Dosage-

10mCi ( 370 MBq )

Pregnancy -
Give Iobuguane I 123 to a pregnant women only if clearly needed

Lactation-
Consider interrupting breast feeding for 6 days  after iobeguane I 123 
administration  in order to minimise risks to breast- feeding infants

Children-
Safety and effectivness in 1 month to 16 years of age have not been studied

Elderly -
Consider assesssment of renal function  in elderly patients prior to
iobenguane administration